시장보고서

상품코드

1772409

외용약 CDMO 시장 규모, 점유율, 동향 분석 리포트 : 제형별, 서비스별, 최종 용도별, 지역별, 부문 예측(2025-2033년)

Topical Drugs CDMO Market Size, Share & Trends Analysis Report By Formulation (Semi-solid Formulations, Liquid Formulations Drugs, Solid Formulations, Transdermal Products), By Service, By End-use, By Region, And Segment Forecasts, 2025 - 2033

발행일: 2025년 06월 | 리서치사:

Grand View Research | 페이지 정보: 영문 120 Pages | 배송안내 : 2-10일 (영업일 기준)

샘플 요청 목록에 추가

※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

외용약 CDMO 시장의 성장과 동향 :

Grand View Research, Inc.의 최신 리포트에 따르면 세계의 외용약 CDMO 시장 규모는 2033년까지 142억 2,000만 달러에 달하며, 2025-2033년의 CAGR은 7.5%를 기록할 것으로 예측됩니다.

다양한 피부 관련 질환 및 피부과 질환을 치료하기 위한 특수 외용제에 대한 수요가 증가하고 있습니다. 의료진과 환자들은 맞춤형 솔루션을 원하고 있으며, 이는 외용제에 대한 전문성을 갖춘 CDMO에 대한 수요 증가로 이어지고 있습니다.

시장은 세분화되어 있으며, 여러 기업이 유사한 기술력과 가공 능력을 보유하고 있습니다. 마이크로 에멀전, 나노테크놀러지, 경피 패치와 같은 혁신적인 약물전달 기술의 개발로 CDMO의 능력은 보다 환자 친화적이고 효과적인 외용제를 개발할 수 있는 능력을 향상시키고 있습니다. 또한 맞춤형 의료에 대한 관심이 높아짐에 따라 CDMO 수요가 크게 증가하고 있는데, 이는 CDMO가 환자 개개인의 상태와 필요에 따라 외용제 치료를 맞춤화하는 데 있으며, 기본적인 역할을 하기 때문입니다.

CDMO와 제약회사 간의 협업이 증가하고 있으며, CDMO는 혁신적이고 새로운 외용제의 제조 및 개발에 기여하고 있습니다. 제약사는 연구, 유통, 마케팅 등 핵심 역량에 집중하는 한편, 제조 서비스를 전문 CDMO에 위탁하는 아웃소싱을 선택하는 경우가 많습니다. 외용제의 FDA 승인 및 제품 출시 증가는 외용제 제조 전문 CDMO의 성장에 크게 기여하고 있습니다. 예를 들어 2022년 5월 더마밴트 사이언스는 미국 식품의약국(FDA)으로부터 VTAMA(타피나로프) 크림 1%를 성인 심상성 건선 국소 치료제로 승인받았습니다.

COVID-19 팬데믹은 시장에 부정적인 영향을 미쳤습니다. 팬데믹은 세계 공급망에 큰 혼란을 일으켜 제조 능력과 원자재 수급에 영향을 미쳤습니다. 외용제를 포함한 일부 임상시험은 안전성 우려로 인해 일시적으로 연기되거나 보류되었습니다. 이로 인해 새로운 외용제 치료제와 제제의 시험 및 개발이 중단되었습니다. 그러나 인수 및 전문 의약품 공급자와의 제휴와 같은 전략적 구상을 채택함으로써 업계는 2021년까지 시장 점유율을 회복할 수 있었습니다.

외용제 CDMO 시장 보고서 하이라이트

제형별로는 반고체 제제 부문이 2024년 66.44%로 가장 큰 매출 점유율을 차지했습니다. 이 분야는 크림, 젤, 연고에 대한 수요 증가와 외용제를 포함한 임상시험 증가에 의해 주도되고 있습니다. 한편, 크림의 하위 카테고리는 여러 질환에 대한 외용 크림의 승인 증가로 인해 큰 점유율을 차지했습니다.
서비스별로는 수탁제조 부문이 2024년 가장 큰 매출 점유율을 차지했습니다. 이 부문의 높은 점유율은 주로 수탁제조의 비용 효율성에 힘입어 수탁제조 서비스에 대한 수요가 증가하고 있기 때문입니다.
최종 용도별로는 외용제 개발 관련 연구개발 활동이 활발해짐에 따라 바이오제약 기업이 예측 기간 중 가장 높은 CAGR을 나타낼 것으로 예측됩니다.
아시아태평양은 예측 기간 중 높은 CAGR을 나타낼 것으로 예측됩니다. 이 지역의 큰 성장은 주로 아시아의 여러 경제권에서 인건비와 운영 비용이 낮기 때문에 외용 제품의 비용 효율적인 제조에 기인합니다.

시장 계통 전망
- 모시장 전망
- 관련/보조 시장 전망
시장 역학
- 시장 성장 촉진요인 분석
- 시장 성장 억제요인 분석
테크놀러지 상황
가격 모델 분석
연구개발비 분석(2021-2024년)
시장 분석 툴
- Porter's Five Forces 분석
- SWOT 분석에 의한 PESTEL

제4장 외용약 CDMO 시장 : 제형별 추정·동향 분석

외용약 CDMO 시장, 제형별 : 부문 대시보드
외용약 CDMO 시장, 제형별 : 변동 분석
제형별, 2021-2033년
반고형 제제
- 크림
- 연고
- 겔
- 기타
액체 제제
고형 제제
경피 흡수형 제품

제5장 외용약 CDMO 시장 : 서비스별 추정·동향 분석별 지표

외용약 CDMO 시장, 서비스별 부문 대시보드
외용약 CDMO 시장, 서비스별 : 변동 분석
서비스별, 2021-2033년
수탁 개발
수탁제조

제6장 외용약 CDMO 시장 : 최종 용도 추정·동향 분석

외용약 CDMO 시장, 최종 용도별 : 부문 대시보드
외용약 CDMO 시장, 최종 용도별 : 변동 분석
최종 용도별, 2021-2033년
제약회사
바이오의약품 기업
기타

제7장 외용약 CDMO 시장 : 지역별 추정·동향 분석

지역별 시장 대시보드
지역별 시장 점유율 분석, 2024년 및 2033년
북미
- 미국
- 캐나다
- 멕시코
유럽
- 영국
- 독일
- 프랑스
- 이탈리아
- 스페인
- 덴마크
- 스웨덴
- 노르웨이
아시아태평양
- 일본
- 중국
- 인도
- 호주
- 태국
- 한국
라틴아메리카
- 브라질
- 아르헨티나
중동 및 아프리카
- 남아프리카공화국
- 사우디아라비아
- 아랍에미리트
- 쿠웨이트

제8장 경쟁 구도

참여 기업
시장 현황 분석, 2024년(히트맵 분석)
기업 개요
- Lubrizol Life Science
- Cambrex Corporation
- Contract Pharmaceuticals Limited
- Bora Pharmaceutical CDMO
- Ascendia Pharmaceuticals
- Pierre Fabre group
- Piramal Pharma Solutions
- DPT Laboratories, LTD
- MedPharm Ltd
- PCI Pharma Services

제9장 주요 권장사항

KSA

Topical Drugs CDMO Market Growth & Trends:

The global topical drugs CDMO market size is expected to reach USD 14.22 billion by 2033, registering a CAGR of 7.5% from 2025 to 2033, according to a new report by Grand View Research, Inc. There is an increasing need for specialized topical drugs to address various skin-related and dermatological conditions. Healthcare providers and patients seek customized solutions, leading to a rise in demand for CDMOs with specialized expertise in topical drugs.

The market is fragmented, with several players having similar technological and processing capabilities. The development of innovative drug delivery technologies, such as microemulsions, nanotechnology, and transdermal patches, has extended the abilities of CDMOs to create more patient-friendly and effective topical drug products. Furthermore, a growing trend towards personalized medicine has significantly boosted demand for topical drug CDMOs, as they play a fundamental role in personalizing topical treatments to individual patient conditions and needs.

Collaborations between CDMOs and pharmaceutical companies have risen, with CDMOs contributing to the manufacturing and development of innovative and new topical drugs. Pharmaceutical firms significantly opt for outsourcing with an aim to focus on core competencies such as research, distribution, and marketing while entrusting manufacturing services to dedicated CDMOs. The increasing number of FDA approvals and product launches in topical medications significantly contributes to CDMOs specializing in topical drug manufacturing growth. For instance, in May 2022, Dermavant Sciences received the U.S. Food and Drug Administration (FDA) approval for its VTAMA (tapinarof) cream, 1%, for the topical management of plaque psoriasis in adults.

The COVID-19 pandemic negatively impacted the market. The pandemic has significantly disrupted the global supply chains, affecting the accessibility of manufacturing capabilities and raw materials. Several clinical studies, including those for topical medicine, were temporarily delayed or put on hold owing to safety concerns. This disturbed the testing and development of new topical drug treatments and formulations. However, by adopting strategic initiatives such as acquisition and partnerships with specialized drug providers, the industry regained its market shares by 2021.

Topical Drugs CDMO Market Report Highlights:

Based on formulation, the semi-solid formulations segment held the largest revenue share of 66.44% in 2024.The segment is driven by the growing demand for creams, gels, and ointments and the rise in clinical trials involving topical drugs. The cream sub-category, on the other hand, held the lion's share owing to increasing approval of topical creams for several medical conditions.
Based on the service, the contract manufacturing segment held the largest revenue share in 2024. The high shares of the segment are majorly due to the growing demand for outsourced manufacturing services, driven by the cost-effectiveness of outsourced manufacturing.
In terms of end-use, the biopharmaceutical companies segment is anticipated to witness highest CAGR during the forecast period owing to the rise in focus on R&D activities pertaining to the development of topical medication.
Asia Pacific is anticipated to register the significant CAGR over the forecast period. The region's substantial growth is primarily attributed to the cost-effective manufacturing of topical products due to lower labor and operational costs in several Asian economies.

Chapter 1. Research Methodology and Scope

1.1. Market Segmentation & Scope
1.2. Segment Definitions
- 1.2.1. Formulation
- 1.2.2. Service
- 1.2.3. End Use
1.3. Research Methodology
1.4. Information Procurement
- 1.4.1. Purchased Database
- 1.4.2. GVR's Internal Database
- 1.4.3. Secondary Sources
- 1.4.4. Primary Research
1.5. Information Or Data Analysis
- 1.5.1. Data Analysis Models
1.6. Market Formulation & Validation
1.7. Model Details
- 1.7.1. Commodity Flow Analysis
- 1.7.2. Parent Market Analysis
1.8. List Of Secondary Sources
1.9. List Of Abbreviations
1.10. Objectives

Chapter 2. Executive Summary

2.1. Market Outlook
2.2. Segment Outlook
2.3. Competitive Insights

Chapter 3. Topical Drugs CDMO Market Variables, Trends & Scope

3.1. Market Lineage Outlook
- 3.1.1. Parent Market Outlook
- 3.1.2. Related/Ancillary Market Outlook
3.2. Market Dynamics
- 3.2.1. Market Driver Analysis
  - 3.2.1.1. High demand for non-invasive treatment options to boost sales of topical drugs
  - 3.2.1.2. Growing pipeline of topical drugs
  - 3.2.1.3. Growing research and development investments
- 3.2.2. Market Restraint Analysis
  - 3.2.2.1. Compliance with strict regulatory requirements
  - 3.2.2.2. Limited efficacy in certain conditions limits adoption of topical products
3.3. Technology Landscape
3.4. Pricing Model Analysis
3.5. R&D Spending Analysis (2021-2024)
3.6. Market Analysis Tools
- 3.6.1. Porter's Five Force Analysis
- 3.6.2. PESTEL by SWOT Analysis

Chapter 4. Topical Drugs CDMO Market: Formulation Estimates & Trend Analysis

4.1. Topical Drugs CDMO Market, By Formulation: Segment Dashboard
4.2. Topical Drugs CDMO Market, By Formulation: Movement Analysis
4.3. Topical Drugs CDMO Market Estimates & Forecasts, By Formulation, 2021 - 2033 (USD Million)
4.4. Semi-solid Formulations
- 4.4.1. Semi-Solid Formulations Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 4.4.2. Creams
  - 4.4.2.1. Creams Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 4.4.3. Ointments
  - 4.4.3.1. Ointments Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 4.4.4. Gel
  - 4.4.4.1. Gel Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 4.4.5. Others
  - 4.4.5.1. Others Market Estimates and Forecasts, 2021 - 2033 (USD Million)
4.5. Liquid Formulations
- 4.5.1. Liquid Formulations Market Estimates and Forecasts, 2021 - 2033 (USD Million)
4.6. Solid Formulations
- 4.6.1. Solid Formulations Market Estimates and Forecasts, 2021 - 2033 (USD Million)
4.7. Transdermal Products
- 4.7.1. Transdermal Products Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 5. Topical Drugs CDMO Market: Service Estimates & Trend Analysis

5.1. Topical Drugs CDMO Market, Service: Segment Dashboard
5.2. Topical Drugs CDMO Market, Service: Movement Analysis
5.3. Topical Drugs CDMO Market Estimates & Forecasts, Indication by Study Design, 2021 - 2033 (USD Million)
5.4. Contract Development
- 5.4.1. Contract Development Market Estimates and Forecasts, 2021 - 2033 (USD Million)
5.5. Contract Manufacturing
- 5.5.1. Contract Manufacturing Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 6. Topical Drugs CDMO Market: End Use Estimates & Trend Analysis

6.1. Topical Drugs CDMO Market, By End Use: Segment Dashboard
6.2. Topical Drugs CDMO Market, By End Use: Movement Analysis
6.3. Topical Drugs CDMO Market Estimates & Forecasts, By End Use, 2021 - 2033 (USD Million)
6.4. Pharmaceutical Companies
- 6.4.1. Pharmaceutical Companies Market Estimates and Forecasts, 2021 - 2033 (USD Million)
6.5. Biopharmaceutical Companies
- 6.5.1. Biopharmaceutical Companies Market Estimates and Forecasts, 2021 - 2033 (USD Million)
6.6. Others
- 6.6.1. Others Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 7. Topical Drugs CDMO Market: Regional Estimates & Trend Analysis

7.1. Regional Market Dashboard
7.2. Regional Market Share Analysis, 2024 & 2033
7.3. North America
- 7.3.1. North America Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.3.2. U.S
  - 7.3.2.1. Key Country Dynamics
  - 7.3.2.2. Competitive Scenario
  - 7.3.2.3. Regulatory Framework
  - 7.3.2.4. U.S. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.3.3. Canada
  - 7.3.3.1. Key Country Dynamics
  - 7.3.3.2. Competitive Scenario
  - 7.3.3.3. Regulatory Framework
  - 7.3.3.4. Canada Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.3.4. Mexico
  - 7.3.4.1. Key Country Dynamics
  - 7.3.4.2. Competitive Scenario
  - 7.3.4.3. Regulatory Framework
  - 7.3.4.4. Mexico Market Estimates and Forecasts, 2021 - 2033 (USD Million)
7.4. Europe
- 7.4.1. Europe Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.4.2. UK
  - 7.4.2.1. Key Country Dynamics
  - 7.4.2.2. Competitive Scenario
  - 7.4.2.3. Regulatory Framework
  - 7.4.2.4. UK Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.4.3. Germany
  - 7.4.3.1. Key Country Dynamics
  - 7.4.3.2. Competitive Scenario
  - 7.4.3.3. Regulatory Framework
  - 7.4.3.4. Germany Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.4.4. France
  - 7.4.4.1. Key Country Dynamics
  - 7.4.4.2. Competitive Scenario
  - 7.4.4.3. Regulatory Framework
  - 7.4.4.4. France Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.4.5. Italy
  - 7.4.5.1. Key Country Dynamics
  - 7.4.5.2. Competitive Scenario
  - 7.4.5.3. Regulatory Framework
  - 7.4.5.4. Italy Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.4.6. Spain
  - 7.4.6.1. Key Country Dynamics
  - 7.4.6.2. Competitive Scenario
  - 7.4.6.3. Regulatory Framework
  - 7.4.6.4. Spain Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.4.7. Denmark
  - 7.4.7.1. Key Country Dynamics
  - 7.4.7.2. Competitive Scenario
  - 7.4.7.3. Regulatory Framework
  - 7.4.7.4. Denmark Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.4.8. Sweden
  - 7.4.8.1. Key Country Dynamics
  - 7.4.8.2. Competitive Scenario
  - 7.4.8.3. Regulatory Framework
  - 7.4.8.4. Sweden Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.4.9. Norway
  - 7.4.9.1. Key Country Dynamics
  - 7.4.9.2. Competitive Scenario
  - 7.4.9.3. Regulatory Framework
  - 7.4.9.4. Norway Market Estimates and Forecasts, 2021 - 2033 (USD Million)
7.5. Asia Pacific
- 7.5.1. Asia Pacific Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.5.2. Japan
  - 7.5.2.1. Key Country Dynamics
  - 7.5.2.2. Competitive Scenario
  - 7.5.2.3. Regulatory Framework
  - 7.5.2.4. Japan Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.5.3. China
  - 7.5.3.1. Key Country Dynamics
  - 7.5.3.2. Competitive Scenario
  - 7.5.3.3. Regulatory Framework
  - 7.5.3.4. China Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.5.4. India
  - 7.5.4.1. Key Country Dynamics
  - 7.5.4.2. Competitive Scenario
  - 7.5.4.3. Regulatory Framework
  - 7.5.4.4. India Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.5.5. Australia
  - 7.5.5.1. Key Country Dynamics
  - 7.5.5.2. Competitive Scenario
  - 7.5.5.3. Regulatory Framework
  - 7.5.5.4. Australia Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.5.6. Thailand
  - 7.5.6.1. Key Country Dynamics
  - 7.5.6.2. Competitive Scenario
  - 7.5.6.3. Regulatory Framework
  - 7.5.6.4. Thailand Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.5.7. South Korea
  - 7.5.7.1. Key Country Dynamics
  - 7.5.7.2. Competitive Scenario
  - 7.5.7.3. Regulatory Framework
  - 7.5.7.4. South Korea Market Estimates and Forecasts, 2021 - 2033 (USD Million)
7.6. Latin America
- 7.6.1. Latin America Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.6.2. Brazil
  - 7.6.2.1. Key Country Dynamics
  - 7.6.2.2. Competitive Scenario
  - 7.6.2.3. Regulatory Framework
  - 7.6.2.4. Brazil Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.6.3. Argentina
  - 7.6.3.1. Key Country Dynamics
  - 7.6.3.2. Competitive Scenario
  - 7.6.3.3. Regulatory Framework
  - 7.6.3.4. Argentina Market Estimates and Forecasts, 2021 - 2033 (USD Million)
7.7. MEA
- 7.7.1. MEA Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.7.2. South Africa
  - 7.7.2.1. Key Country Dynamics
  - 7.7.2.2. Competitive Scenario
  - 7.7.2.3. Regulatory Framework
  - 7.7.2.4. South Africa Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.7.3. Saudi Arabia
  - 7.7.3.1. Key Country Dynamics
  - 7.7.3.2. Competitive Scenario
  - 7.7.3.3. Regulatory Framework
  - 7.7.3.4. Saudi Arabia Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.7.4. UAE
  - 7.7.4.1. Key Country Dynamics
  - 7.7.4.2. Competitive Scenario
  - 7.7.4.3. Regulatory Framework
  - 7.7.4.4. UAE Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.7.5. Kuwait
  - 7.7.5.1. Key Country Dynamics
  - 7.7.5.2. Competitive Scenario
  - 7.7.5.3. Regulatory Framework
  - 7.7.5.4. Kuwait Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 8. Competitive Landscape

8.1. Participant Categorization
8.2. Market Position Analysis, 2024 (Heat Map Analysis)
8.3. Company Profiles
- 8.3.1. Lubrizol Life Science
  - 8.3.1.1. Company Overview
  - 8.3.1.2. Financial Performance
  - 8.3.1.3. Service Benchmarking
  - 8.3.1.4. Strategic Initiatives
- 8.3.2. Cambrex Corporation
  - 8.3.2.1. Company Overview
  - 8.3.2.2. Financial Performance
  - 8.3.2.3. Service Benchmarking
  - 8.3.2.4. Strategic Initiatives
- 8.3.3. Contract Pharmaceuticals Limited
  - 8.3.3.1. Company Overview
  - 8.3.3.2. Financial Performance
  - 8.3.3.3. Service Benchmarking
  - 8.3.3.4. Strategic Initiatives
- 8.3.4. Bora Pharmaceutical CDMO
  - 8.3.4.1. Company Overview
  - 8.3.4.2. Financial Performance
  - 8.3.4.3. Service Benchmarking
  - 8.3.4.4. Strategic Initiatives
- 8.3.5. Ascendia Pharmaceuticals
  - 8.3.5.1. Company Overview
  - 8.3.5.2. Financial Performance
  - 8.3.5.3. Service Benchmarking
  - 8.3.5.4. Strategic Initiatives
- 8.3.6. Pierre Fabre group
  - 8.3.6.1. Company Overview
  - 8.3.6.2. Financial Performance
  - 8.3.6.3. Service Benchmarking
  - 8.3.6.4. Strategic Initiatives
- 8.3.7. Piramal Pharma Solutions
  - 8.3.7.1. Company Overview
  - 8.3.7.2. Financial Performance
  - 8.3.7.3. Service Benchmarking
  - 8.3.7.4. Strategic Initiatives
- 8.3.8. DPT Laboratories, LTD
  - 8.3.8.1. Company Overview
  - 8.3.8.2. Financial Performance
  - 8.3.8.3. Service Benchmarking
  - 8.3.8.4. Strategic Initiatives
- 8.3.9. MedPharm Ltd
  - 8.3.9.1. Company Overview
  - 8.3.9.2. Financial Performance
  - 8.3.9.3. Service Benchmarking
  - 8.3.9.4. Strategic Initiatives
- 8.3.10. PCI Pharma Services
  - 8.3.10.1. Company Overview
  - 8.3.10.2. Financial Performance
  - 8.3.10.3. Service Benchmarking
  - 8.3.10.4. Strategic Initiatives